Cara Therapeutics (NASDAQ:CARA) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Up 10.7 %

Shares of NASDAQ:CARA opened at $5.70 on Friday. The stock has a market cap of $26.07 million, a PE ratio of -0.27 and a beta of 0.50. The company’s fifty day moving average is $4.99 and its 200 day moving average is $4.19. Cara Therapeutics has a 52 week low of $2.71 and a 52 week high of $11.52.

Institutional Trading of Cara Therapeutics

A number of institutional investors have recently made changes to their positions in CARA. FMR LLC raised its holdings in Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 32,789 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Cara Therapeutics in the third quarter valued at about $29,000. Rockefeller Capital Management L.P. bought a new position in shares of Cara Therapeutics during the fourth quarter valued at about $953,000. Curi RMB Capital LLC purchased a new stake in shares of Cara Therapeutics during the fourth quarter worth about $277,000. Finally, Shay Capital LLC bought a new stake in shares of Cara Therapeutics in the fourth quarter worth about $524,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.